ProfileGDS5678 / 1436162_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 36% 37% 37% 35% 35% 35% 37% 37% 36% 37% 37% 36% 42% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8611136
GSM967853U87-EV human glioblastoma xenograft - Control 22.847437
GSM967854U87-EV human glioblastoma xenograft - Control 32.8488537
GSM967855U87-EV human glioblastoma xenograft - Control 42.7549235
GSM967856U87-EV human glioblastoma xenograft - Control 52.758235
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8838235
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9087337
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.833137
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7873936
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8383837
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8326637
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7844436
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9703442
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8597338